U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06918951) titled 'Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers' on March 10.
Brief Summary: STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm.
Participants, enrolling oncologists, and the statistician will be blinded to trial arm assignment.
In the control arm, radiotherapy will consist of 8 Gy in 1 fraction to all sites of oligoprogression, and the experimental arm will consist of SABR treatment to all sites of oligop...